medigraphic.com
ISSN 0185-6014 (Print)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2018, Number 1

<< Back Next >>

Rev Mex Patol Clin Med Lab 2018; 65 (1)

Bordetella pertussis: re-emergence

Cervantes GE

Language: Spanish
References: 21
Page: 18-21
PDF size: 224.25 Kb.


ABSTRACT

Despite vaccination strategies worldwide, Bordetella pertussis has become a public health problem; it remains one of the least vaccine-preventable diseases in the world, with extensive coverage of vaccination. In this article, the main mechanisms of virulence associated with the infection through which the bacterium manages to evade the immune response are described, as well as a current picture of the state of immunization against B. pertussis and the problem of its re-emergence worldwide. As confirmed by recent studies, the increased risk of B. pertussis infection continues to occur in adolescents and adults due to the decrease in the immune response induced by vaccination and natural infection. Current information indicates that whooping cough is re-emerging around the world; therefore, a timely diagnosis and treatment are necessary.


REFERENCES

  1. Gambhir M, Clark TA, Cauchemez S, Tartof SY, Swerdlow DL, Ferguson NM. A change in vaccine efficacy and duration of protection explains recent rises in pertussis incidence in the United States. PLoS Comput Biol. 2015; 11 (4): e1004138.

  2. Centers for Disease Control and Prevention. Pertussis. In: Atkinson W, Wolfe S, Hamborsky J, editors. Epidemiology and prevention of vaccine-preventable diseases. Washington DC: Public Health Foundation; 2012. pp. 215-232.

  3. Cherry JD. Why do pertussis vaccines fail? Pediatrics. 2012; 129 (5): 968-970.

  4. Bart MJ, Harris SR, Advani A, Arakawa Y, Bottero D, Bouchez V et al. Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio. 2014; 5 (2): e01074.

  5. Warfel JM, Beren J, Merkel TJ. Airborne transmission of Bordetella pertussis. J Infect Dis. 2012; 206 (6): 902-906.

  6. Paddock CD, Sanden GN, Cherry JD, Gal AA, Langston C, Tatti KM et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants. Clin Infect Dis. 2008; 47 (3): 328-338.

  7. Preston A, Maskell DJ. A new era of research into Bordetella pertussis pathogenesis. J Infect. 2002; 44 (1): 13-16.

  8. Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP et al. Pertussis pathogenesis —what we know and what we don’t know. J Infect Dis. 2014; 209 (7): 982-985.

  9. Melvin JA, Scheller EV, Miller JF, Cotter PA. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol. 2014; 12 (4): 274-288.

  10. He Q, Mertsola J. Factors contributing to pertussis resurgence. Future Microbiol. 2008; (3): 329-339.

  11. Carbonetti NH. Bordetella pertussis: new concepts in pathogenesis and treatment. Curr Opin Infect Dis. 2016; 29 (3): 287-294.

  12. De Gouw D, Diavatopoulos DA, Bootsma HJ, Hermans PW, Mooi FR. Pertussis: a matter of immune modulation. FEMS Microbiol Rev. 2011; 35 (3): 441-474.

  13. Belcher T, Preston A. Bordetella pertussis evolution in the (functional) genomics era. Pathog Dis. 2015; 73 (8): ftv064.

  14. Safarchi A, Octavia S, Luu LD, Tay CY, Sintchenko V, Wood N et al. Pertactin negative Bordetella pertussis demonstrates higher fitness under vaccine selection pressure in a mixed infection model. Vaccine. 2015; 33 (46): 6277-6281.

  15. Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N. First report and detailed characterization of B. pertussis isolates not expressing pertussis toxin or pertactin. Vaccine. 2009; 27 (43): 6034-6041.

  16. Bouchez V, Hegerle N, Strati F, Njamkepo E, Guiso N. New data on vaccine antigen deficient Bordetella pertussis isolates. Vaccines (Basel). 2015; 3 (3): 751-770.

  17. Mooi FR, Van Der Maas NA, De Melker HE. Pertussis resurgence: waning immunity and pathogen adaptation —two sides of the same coin. Epidemiol Infect. 2014; 142 (4): 685-694.

  18. King AJ, van Gorkom T, Pennings JL, van der Heide HG, He Q, Diavatopoulos D et al. Comparative genomic profiling of Dutch clinical Bordetella pertussis isolates using DNA microarrays: identification of genes absent from epidemic strains. BMC Genomics. 2008; 9: 311.

  19. Mooi FR, van Loo IH, van Gent M, He Q, Bart MJ, Heuvelman KJ et al. Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis. 2009; 15 (8): 1206-1213.

  20. Coutte L, Locht C. Investigating pertussis toxin and its impact on vaccination. Future Microbiol. 2015; 10 (2): 241-254.

  21. Clarke M, McIntyre PB, Blyth CC, Wood N, Octavia S, Sintchenko V et al. The relationship between Bordetella pertussis genotype and clinical severity in Australian children with pertussis. J Infect. 2016; 72 (2): 171-178.




2020     |     www.medigraphic.com